Stock listing
BDTX Stock Price, News, Filings & Events — Black Diamond Therapeutics, Inc.
Selected listing: BDTX · NASDAQ · USD · US
This page tracks Black Diamond Therapeutics, Inc.'s BDTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BDTX:NASDAQ. BDTX:NASDAQ is the stock-level entry point for investors researching Black Diamond Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Black Diamond Therapeutics, Inc. is a public company traded under the ticker BDTX in the American market. The company has a market capitalization of approximately $102.57 million. Black Diamond focuses on developing innovative therapies for various medical conditions.
- Ticker
- BDTX:NASDAQ
- Asset type
- Stock
- Market cap
- $113.8M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Black Diamond Therapeutics, Inc. BDTX:NASDAQ stock context
This page tracks Black Diamond Therapeutics, Inc.'s BDTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BDTX:NASDAQ. BDTX:NASDAQ is the stock-level entry point for investors researching Black Diamond Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Black Diamond Therapeutics, Inc. is a public company traded under the ticker BDTX in the American market. The company has a market capitalization of approximately $102.57 million. Black Diamond focuses on developing innovative therapies for various medical conditions.
Latest news from Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
BioCardia : Aug 24 - BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-on De No...
August 24, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
Research Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for BDTX:NASDAQ.
Black Diamond Therapeutics, Inc. company profile
View the public company page for Black Diamond Therapeutics, Inc. on 6ix.
Black Diamond Therapeutics, Inc. news
Read company news and market updates connected to Black Diamond Therapeutics, Inc..
Black Diamond Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Black Diamond Therapeutics, Inc..